Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 183

1.

A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.

Inoyama D, Awasthi D, Capodagli GC, Tsotetsi K, Sukheja P, Zimmerman M, Li SG, Jadhav R, Russo R, Wang X, Grady C, Richmann T, Shrestha R, Li L, Ahn YM, Ho Liang HP, Mina M, Park S, Perlin DS, Connell N, Dartois V, Alland D, Neiditch MB, Kumar P, Freundlich JS.

Cell Chem Biol. 2020 Mar 19. pii: S2451-9456(20)30071-4. doi: 10.1016/j.chembiol.2020.02.007. [Epub ahead of print]

PMID:
32197094
2.

Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies.

Sfeir MM, Jiménez-Ortigosa C, Gamaletsou MN, Schuetz AN, Soave R, Besien KV, Small CB, Perlin DS, Walsh TJ.

J Fungi (Basel). 2020 Jan 31;6(1). pii: E20. doi: 10.3390/jof6010020.

3.

Cell Wall-Modifying Antifungal Drugs.

Perlin DS.

Curr Top Microbiol Immunol. 2019 Dec 25. doi: 10.1007/82_2019_188. [Epub ahead of print]

PMID:
31875267
4.

Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Lee A, Prideaux B, Zimmerman M, Carter C, Barat S, Angulo D, Dartois V, Perlin DS, Zhao Y.

Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e02268-19. doi: 10.1128/AAC.02268-19. Print 2020 Feb 21.

PMID:
31871074
5.

Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata.

Hou X, Healey KR, Shor E, Kordalewska M, Ortigosa CJ, Paderu P, Xiao M, Wang H, Zhao Y, Lin LY, Zhang YH, Li YZ, Xu YC, Perlin DS, Zhao Y.

Emerg Microbes Infect. 2019;8(1):1619-1625. doi: 10.1080/22221751.2019.1684209.

6.

Detection of Candida auris antifungal drug resistance markers directly from clinical skin swabs.

Kordalewska M, Lee A, Zhao Y, Perlin DS.

Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01754-19. doi: 10.1128/AAC.01754-19. [Epub ahead of print]

PMID:
31591112
7.

Identification of Drug Resistant Candida auris.

Kordalewska M, Perlin DS.

Front Microbiol. 2019 Aug 20;10:1918. doi: 10.3389/fmicb.2019.01918. eCollection 2019. Review.

8.

Molecular Diagnostics in the Times of Surveillance for Candida auris.

Kordalewska M, Perlin DS.

J Fungi (Basel). 2019 Aug 20;5(3). pii: E77. doi: 10.3390/jof5030077. Review.

9.

Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis.

Prépost E, Tóth Z, Perlin DS, Gesztelyi R, Kardos G, Kovács R, Nagy F, Forgács L, Majoros L.

Infect Drug Resist. 2019 Jul 1;12:1805-1814. doi: 10.2147/IDR.S198764. eCollection 2019.

10.

Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.

Satish S, Jiménez-Ortigosa C, Zhao Y, Lee MH, Dolgov E, Krüger T, Park S, Denning DW, Kniemeyer O, Brakhage AA, Perlin DS.

mBio. 2019 Jun 4;10(3). pii: e00779-19. doi: 10.1128/mBio.00779-19.

11.

Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species.

Meletiadis J, Siopi M, Kanioura L, Jørgensen KM, Perlin DS, Mouton JW, Arendrup MC.

J Antimicrob Chemother. 2019 Aug 1;74(8):2247-2254. doi: 10.1093/jac/dkz154.

PMID:
31106352
12.

Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE, Chen L, Kreiswirth BN, Ellis-Grosse EJ, Drusano GL, Perlin DS, Bonomo RA.

J Infect Dis. 2019 Jul 19;220(4):666-676. doi: 10.1093/infdis/jiz149.

PMID:
31099835
13.

Adipose Tissue Regulates Pulmonary Pathology during TB Infection.

Ayyappan JP, Ganapathi U, Lizardo K, Vinnard C, Subbian S, Perlin DS, Nagajyothi JF.

mBio. 2019 Apr 16;10(2). pii: e02771-18. doi: 10.1128/mBio.02771-18.

14.

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.

Lee A, Prideaux B, Lee MH, Zimmerman M, Dolgov E, Perlin DS, Zhao Y.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00524-19. doi: 10.1128/AAC.00524-19. Print 2019 Jun.

15.

Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.

Fontana L, Perlin DS, Zhao Y, Noble BN, Lewis JS, Strasfeld L, Hakki M.

Clin Infect Dis. 2020 Feb 14;70(5):723-730. doi: 10.1093/cid/ciz282.

PMID:
30958538
16.

Beyond tissue concentrations: antifungal penetration at the site of infection.

Zhao Y, Prideaux B, Baistrocchi S, Sheppard DC, Perlin DS.

Med Mycol. 2019 Apr 1;57(Supplement_2):S161-S167. doi: 10.1093/mmy/myy067. Review.

17.

A Novel, Drug Resistance-Independent, Fluorescence-Based Approach To Measure Mutation Rates in Microbial Pathogens.

Shor E, Schuyler J, Perlin DS.

mBio. 2019 Feb 26;10(1). pii: e00120-19. doi: 10.1128/mBio.00120-19.

18.

A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs.

Wiedman GR, Zhao Y, Perlin DS.

mSphere. 2018 Dec 19;3(6). pii: e00623-18. doi: 10.1128/mSphere.00623-18.

19.

Rapid Detection of ERG11-Associated Azole Resistance and FKS-Associated Echinocandin Resistance in Candida auris.

Hou X, Lee A, Jiménez-Ortigosa C, Kordalewska M, Perlin DS, Zhao Y.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01811-18. doi: 10.1128/AAC.01811-18. Print 2019 Jan.

20.

Spontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrata.

Shields RK, Kline EG, Healey KR, Kordalewska M, Perlin DS, Nguyen MH, Clancy CJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01692-18. doi: 10.1128/AAC.01692-18. Print 2019 Jan.

Supplemental Content

Loading ...
Support Center